Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 14, 2014 - Issue 3
Submit an article Journal homepage
497
Views
11
CrossRef citations to date
0
Altmetric
Original Research

Safety and cost benefit of an accelerated infliximab infusion protocol in the treatment of ambulatory patients with inflammatory bowel diseases

Payal SaxenaConcord Hospital, Gastroenterology and Liver Services, Sydney Local Health District, Sydney, New South Wales, Australia
, MBBS FRACP,
Guang ChenConcord Hospital, Gastroenterology and Liver Services, Sydney Local Health District, Sydney, New South Wales, Australia
, MBBS,
Bilel JidehConcord Hospital, Gastroenterology and Liver Services, Sydney Local Health District, Sydney, New South Wales, Australia
, MBBS,
Glen CollinsConcord Hospital, Gastroenterology and Liver Services, Sydney Local Health District, Sydney, New South Wales, Australia
, RN &
Rupert W LeongConcord Hospital, Gastroenterology and Liver Services, Sydney Local Health District, Level 1 West, ACE Unit, Hospital Rd, Concord NSW 2139, Australia+61 2 9767 6111; +61 2 9767 6767; [email protected]
, MBBS MD FRACP AGAF
Pages 277-282 | Published online: 21 Dec 2013

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Kyle Null, Varun Kumar, Trevor Lissoos & Michelle Luo. (2018) Infusion administration billing for vedolizumab and infliximab in inflammatory bowel disease. Journal of Medical Economics 21:11, pages 1102-1109.
Read now

Articles from other publishers (10)

Blake Rosenthal, Sabreen Aulakh, Perseus V Patel, Jason T Wong & Sabina Ali. (2023) Direct transition from rapid-infusion originator to rapid-infusion biosimilar tumor necrosis factor inhibitor in children with inflammatory bowel disease: A case series. American Journal of Health-System Pharmacy.
Crossref
Suha Abushamma, Ted Walker, Kevin Garza, Ling Chen, Darren Nix & Chien-Huan Chen. (2023) Accelerated Infliximab Infusion Safety and Tolerability Is Non-inferior to Standard Infusion Protocol in Inflammatory Bowel Disease Patients: A Randomized Controlled Study. Crohn's & Colitis 360 5:3.
Crossref
Wan Chee Ong, Miao Shan Lim, Elaine Chan, Thomson Chong Teik Lim, Teong Guan Lim & Webber Chan. (2022) A quality improvement project reduces time spent at an inflammatory bowel disease infusion center with accelerated infliximab infusion protocol. JGH Open 6:7, pages 470-476.
Crossref
Marianne Vulliemoz, Stephan Brand, Pascal Juillerat, Christian Mottet, Shomron Ben-Horin & Pierre Michetti. (2020) TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User’s Guide: An Update. Digestion 101:Suppl. 1, pages 16-26.
Crossref
. (2017) Inflammatory Bowel Disease Clinical. Journal of Gastroenterology and Hepatology 32:S2, pages 121-154.
Crossref
James Berenson, Robert Manges, Suprith Badarinath, Alan Cartmell, Kristi McIntyre, Roger Lyons, Wael Harb, Hesham Mohamed, Ali Nourbakhsh & Robert Rifkin. (2017) A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma. American Journal of Hematology 92:5, pages 460-466.
Crossref
S. Mazzuoli, D. Tricarico, F. Demma, G. Furneri & F. W. Guglielmi. (2016) Accelerated Infliximab Infusion: Safety, Factors Predicting Adverse Events, Patients? Satisfaction and Cost Analysis. A Cohort Study in IBD Patients. PLOS ONE 11:11, pages e0166443.
Crossref
Glen Collins. (2016) Organising infusions: Application administration and complications. Journal of Gastroenterology and Hepatology 31, pages 26-26.
Crossref
Lev Lichtenstein, Yulia Ron, Shmuel Kivity, Shomron Ben-Horin, Eran Israeli, Gerald M. Fraser, Iris Dotan, Yehuda Chowers, Ronit Confino-Cohen & Batia Weiss. (2015) Infliximab-Related Infusion Reactions: Systematic Review. Journal of Crohn's and Colitis 9:9, pages 806-815.
Crossref
Andrea Michielan, Matteo Martinato, Andrea Favarin, Viviana Zanotto, Roberta Caccaro, Antonino Caruso, Giacomo Carlo Sturniolo & Renata D?Inc?. (2015) A nurse-led accelerated procedure for infliximab infusion is well tolerated and effective in patients with inflammatory bowel disease. Digestive and Liver Disease 47:5, pages 372-377.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.